NCT04456868: PHYDDOPA

Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave

Terminated NA Last updated 10 February 2026

What this trial tests

NA trial testing Electroencephalogram in Bipolar Anhedonic Depression in 36 participants. Terminated before completion.

Timeline

24 August 2020

Primary endpoint
10 August 2023

10 August 2023

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	36
Start date	24 August 2020
Primary completion	10 August 2023
Estimated completion	10 August 2023
Sites	2 locations across France

Drugs / interventions tested

• Electroencephalogram
• walking test
• Quality of life questionnaire
• Position emission tomography

Conditions studied

• Bipolar Anhedonic Depression — all drugs for Bipolar Anhedonic Depression →

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 70, any sex, with Bipolar Anhedonic Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Depression is currently the leading cause of disability and suicide death worldwide. Several studies, however, have shown that a significant proportion of patients do not respond to standard antidepressants, especially since their symptomatology is dominated by anhedonia or psychomotor retardation reflecting central dopaminergic dysfunction. In order to improve the efficiency and speed of the antidepressant response, it seems essential to highlight this dopaminergic dysfunction, by defining a P300 wave profile specific to the subtype of depressed patients with anhedonic phenotype to whom personalized treatment targeting dopaminergic transmission could in the future be proposed earlier. The investigators therefore wish to highlight an increase in the latency time of P300 and a modification of motor skills (of the walking cycle and of the movement of the hands), without modification of the dopaminergic transmission measured by PETScan, specific to the sub-type of depressive patients, resistant to at least 2 antidepressants of different classes with an anhedonia score\> 5/14 on the SHAPS scale. The increased latency of P300 could then be used in the future as a predictive biomarker of resistance to conventional antidepressant treatments specific to this population of anhedonic depressed patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.